Blebitis After EX-PRESS XXXX Implantation-A Case Series.

@entity1 @entity4530 @entity14985 @entity726 @entity281 @entity3225
PURPOSE: To present the management and outcomes of blebitis in @entity1 who underwent EX-PRESS @entity726 ( @entity726 ) implantation. DESIGN: Retrospective case series. @entity1 : The study included 5 @entity1 who developed blebitis following EX-PRESS @entity726 implantation. METHODS: Charts of all @entity1 who underwent EX-PRESS @entity726 implantation at the @entity726 Center of San Francisco between 2007 and 2013 were reviewed. Five @entity1 with blebitis were identified and their clinical course was recorded. MAIN OUTCOME MEASURES: Clinical course of blebitis. RESULTS: Of 325 eyes that underwent EX-PRESS @entity726 implantation, 5 eyes (1.5%) with blebitis were identified. The mean interval between EX-PRESS @entity726 surgery and blebitis was 2.3  0.8 years. Four of the 5 eyes with blebitis had potential risk factors for @entity281 ; 1 had chronic @entity14985 , 2 had contact lens use, and one had 2 episodes of @entity4530 before blebitis. All @entity1 were treated with topical antibiotics; in addition, 3 received oral antibiotics and 1 received intravitreal antibiotics. None of the @entity1 developed @entity3225 . One @entity1 had recurrent blebitis, which was treated with topical, oral, and intravitreal antibiotics. None of the @entity1 had the device removed. The mean follow-up time after blebitis was 16.8  8.9 months (range, 10 to 32 mo). CONCLUSIONS: This case series suggests that blebitis after EX-PRESS @entity726 implanted under a scleral flap may be treated without removal of the device. Further study is required to determine the optimal method of treating this condition.
